EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Retrospective Analysis of the Timing of Radiotherapy Intervention After Induction Chemoimmunotherapy in Unresectable Locally Advanced Lung Squamous Cell Carcinoma

Li Zeng, Yu Zhang, Aiju Zeng, Daiyuan Ma

Cancer Management and Research · 2025-07 · Volume 17 · 1301-1311

DOI: 10.2147/cmar.s517837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Management and Research, 2025-07. Verfasst von Li Zeng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal combination of immune checkpoint inhibitors (ICIs), radiotherapy, and chemotherapy for unresectable locally advanced lung squamous cell carcinoma (LA-LUSC) remains undefined. This study evaluated induction chemoimmunotherapy followed by radiotherapy ± consolidation ICI in unresectable LA-LUSC, specifically exploring radiotherapy timing impact.

Methods

We retrospectively analyzed 54 unresectable LA-LUSC patients receiving induction chemoimmunotherapy followed by radiotherapy. Patients were grouped by radiotherapy timing: Early (after 2-3 induction cycles, n = 18) and Late (after 4-6 cycles, n = 36). Survival analysis (Kaplan-Meier, Log-rank) compared progression-free survival (PFS), local PFS (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and safety. Prognostic factors for PFS/OS were explored.

Results

Median follow-up was 30.7 months. Median PFS for all patients was 21.9 months. Early radiotherapy improved PFS (HR = 0.43, p = 0.024) and LPFS (HR = 0.36, p = 0.038). Radiotherapy after 2-3 induction cycles was an independent predictor of improved PFS (p = 0.040). Overall treatment tolerance was good; grade ≥3 pneumonitis incidence was 5.56%. After propensity score matching, OS was significantly longer in patients receiving induction plus consolidation ICI versus induction ICI alone (HR = 0.51, p = 0.038).

Conclusion

Induction chemoimmunotherapy followed by radiotherapy demonstrates promising efficacy and manageable toxicity in unresectable LA-LUSC. Initiating radiotherapy earlier (after 2-3 induction cycles) improves PFS and LPFS and is an independent favorable prognostic factor. Consolidation ICI after combined chemoimmunotherapy and radiotherapy further extends OS compared to induction ICI alone.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorslocally advanced non-small cell lung cancerlung cancerradiotherapy

Autor:innen und Institutionen

  • Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China.

Zitieren

APA

Zeng, L., Zhang, Y., Zeng, A., & Ma, D. (2025). Retrospective Analysis of the Timing of Radiotherapy Intervention After Induction Chemoimmunotherapy in Unresectable Locally Advanced Lung Squamous Cell Carcinoma. Cancer Management and Research, Volume 17, 1301-1311. https://doi.org/10.2147/cmar.s517837

Vancouver

Zeng L, Zhang Y, Zeng A, Ma D. Retrospective Analysis of the Timing of Radiotherapy Intervention After Induction Chemoimmunotherapy in Unresectable Locally Advanced Lung Squamous Cell Carcinoma. Cancer Management and Research. 2025;Volume 17:1301-1311. doi:10.2147/cmar.s517837

BibTeX
@article{Zeng2025,
  author = {Zeng, Li and Zhang, Yu and Zeng, Aiju and Ma, Daiyuan},
  title = {Retrospective Analysis of the Timing of Radiotherapy Intervention After Induction Chemoimmunotherapy in Unresectable Locally Advanced Lung Squamous Cell Carcinoma},
  journal = {Cancer Management and Research},
  year = {2025},
  volume = {Volume 17},
  pages = {1301--1311},
  doi = {10.2147/cmar.s517837}
}
Kostenlos starten →